Subcutaneous Biologics Market Therapeutics, Rising Industry Size, Growth Opportunity, Latest Technology and Development Analysis By Top Key Players, 2019-2026

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Biologic, also known as biopharmaceutical, is a complex medicinal product manufactured by a biological process. There are various types of biologics such as somatic cells, vaccines, and body proteins that are derived from blood and plasma. The biologics is a multibillion-dollar industry and is expanding globally at a significant rate. Although most biologic products are given intravenously, a number of biologics have been developed that are given subcutaneously. The subcutaneous route of administration offers significant advantages over intravenous administration such as ease of drug administration, does not require skilled personnel for drug administration, enables at-home drug delivery and thus reduces patient time at healthcare facilities, reduced medicine cost and increased therapy compliance. These factors have gained enormous traction for subcutaneous biologics in the recent past. Subcutaneous route of drug administration are highly effective in administering biologics such as vaccines, proteins, peptides, antibodies, and other large and complex molecules.

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/74

Global Subcutaneous Biologics Market Taxonomy

There are several subcutaneous biologics available in the market namely Humira (Adalimumab), MabThera/Rituxan (Rituximab), Zytux (Rituximab), Stelara (ustekinumab), Enbrel (Etanercept), Neulasta (filgrastim), ORENCIA (abatacept), RoACTEMRA (tocilizumab) and Herceptin (Trastuzumab). In April 2014, F. Hoffmann-La Roche AG announced the European Commission (EU) approval of its subcutaneous formulation of RoACTEMRA (tocilizumab). Moreover, in 2015, Amgen launched Neulasta delivery kit to automate the delivery of drug and preventing infection in cancer patients. The global market for subcutaneous biologics has been segmented by the aforementioned biologic brands. On the basis of subcutaneous drug delivery systems, the market is categorized as:

• Prefilled syringes
• Wearable injectors
• Auto-injectors
• Drug reconstitution delivery systems.

The global subcutaneous biologics market is also analyzed based on the applications as follows:

• Crohn’s Disease
• Rheumatoid Arthritis
• Breast cancer
• Leukemia
• Lymphoma
• Psoriasis

Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/74

Market Outlook

In terms of geography, the global market for subcutaneous biologics is segmented into four major regions, namely, North America, Europe, Asia Pacific, and Rest of the World (RoW). There has been huge expenditure on healthcare in developed countries such as the U.S. and Canada. Moreover, high prevalence of diseases such as rheumatoid arthritis and breast cancer is expected to drive the market growth. The Centers for Disease Control and Prevention (CDC) estimate that the current prevalence of rheumatoid arthritis (nearly 50 million Americans in 2012) will increase to 78 million by 2040. According to RheumatoidArthritis.org, the disease also affects nearly 300,000 children in the U.S. In the European region, EU-5 countries (Germany, France, United Kingdom, Italy and Spain) are the most potential market owing well established economy of these regions. Convenient drug delivery format is also in demand in developing regions such as Asia Pacific and Latin America where therapy compliance is a major issue. Large undiagnosed population, inadequate access to medicines and affordability issues hinder the market growth for subcutaneous biologics in developing regions.

The global market for subcutaneous biologics will be expanding under the influence of factors such as:

• Advantages over other routes of administration
• Increasing trend of self-medication
• Introduction of innovative drug delivery devices such as auto-injectors and prefilled syringes
• Growing incidence and prevalence of rheumatoid arthritis and breast cancer
• Growth in the biosimilars market

Competitive Landscape

Key players in the global subcutaneous biologics market include Genentech Inc., Biogen Idec, F. Hoffmann-La Roche AG, Amgen, Inc., Eisai, Inc., AbbVie, Inc., Pfizer Ltd., Takeda Pharmaceutical Company Ltd., and Bristol-Myers Squibb.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/74

Key Developments

1. Key players in the market are involved in various business strategies such as gaining biologics license from regulatory authorities. For instance, in July 2018, Halozyme Therapeutics, Inc. announced that the U.S. Food and Drugs Administration (FDA) accepted biologics license from ‘Genentech’, a member of the Roche Group, for subcutaneous formulation of trastuzumab (Herceptin), which is company’s FDA approved indication for breast cancer.
2. Major players in the market are focused on gaining approvals for products and treatment from regulatory authorities, in order to gain competitive edge in the market. For instance, in October 2018, Roche AG received the U.S. Food and Drugs Administration approval for Hemlibra, which is a routine treatment for adults and children suffering from bleeding episode. It consists haemophilia A without factor VIII inhibitors, which will reduce the frequency of bleeding episodes.
3. Major players in the market are focused on gaining approvals for products and treatment from regulatory authorities, in order to gain competitive edge in the market. For instance, in September 2018, AstraZenca and Amgen received the U.S. Food and Drug Administration ‘Breakthrough Therapy Designation’ for tezepelumab, which will be used for patients with severe asthma without an eosinophilic phenotype.

Other Exclusive Reports:

Cancer Biologics Market, by Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, and Immune Checkpoint Inhibitors), By Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, and Others), By Distribution Channel (Hospitals, Clinics, and Others), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Biologics Market, by Drug Class (Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides and Others (Peptide, Botulinum Toxin, and Others)), By Therapeutic Application (Oncology, Metabolic Disorders, Autoimmune/Immunologic Diseases, Ophthalmic Diseases, Inflammatory Bowel Diseases (IBDs), Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders (MSDs), Cardiovascular Diseases (CVDs), Infectious Diseases, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Plant-based Biologics Market, by Plant System (Leaf-based, Seeds-based, Fruits-based, Tubers-based, and Others), By Source (Carrot, Tobacco, Duckweed, Rice, Moss, Alfalfa, and Others), and by Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.